Molecular mechanism of action of pharmacoperone rescue of misrouted GPCR mutants: the GnRH receptor.

No abstract is available for this paper.

• Publication year

  2009

• Venue

  Molecular Endocrinology

• Publication date

  2009-02-01

• Fields of study

  Biology, Medicine, Chemistry

• Identifiers
  DOI 10.1210/me.2008-0384PMID 19095769PMCID PMC2646616
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• G protein-coupled receptors disrupted in human genetic disease.

  2008cited by this paper
• Identification of pharmacological chaperones as potential therapeutic agents to treat phenylketonuria.

  2008cited by this paper
• Drugs and their molecular targets: an updated overview

  2008cited by this paper
• G Protein-Coupled Receptor Trafficking in Health and Disease: Lessons Learned to Prepare for Therapeutic Mutant Rescue in Vivo

  2007cited by this paper
• G-coupled protein receptors and breast cancer progression: potential drug targets.

  2007cited by this paper
• Structure, pharmacology and therapeutic prospects of family C G-protein coupled receptors.

  2007cited by this paper
• Refolding of misfolded mutant GPCR: post-translational pharmacoperone action in vitro.

  2007cited by this paper
• Nephrogenic Diabetes Insipidus

  2006cited by this paper
• Overlapping, nonidentical binding sites of different classes of nonpeptide antagonists for the human gonadotropin-releasing hormone receptor.

  2006cited by this paper
• Nephrogenic diabetes insipidus.

  2006cited by this paper
• Regulation of G Protein-coupled Receptor Trafficking by Inefficient Plasma Membrane Expression

  2006cited by this paper
• Protein folding as posttranslational regulation: evolution of a mechanism for controlled plasma membrane expression of a G protein-coupled receptor.

  2006cited by this paper
• Interaction with the Unfolded Protein Response Reveals a Role for Stargazin in Biosynthetic AMPA Receptor Transport

  2005cited by this paper
• Antagonist and agonist binding models of the human gonadotropin-releasing hormone receptor.

  2005cited by this paper
• Heterodimerization with beta2-adrenergic receptors promotes surface expression and functional activity of alpha1D-adrenergic receptors.

  2005cited by this paper
• Addition of a signal peptide sequence to the α1D‐adrenoceptor gene increases the density of receptors, as determined by [3H]‐prazosin binding in the membranes

  2005cited by this paper
• Inefficient Maturation of the Rat Luteinizing Hormone Receptor

  2005cited by this paper
• Parallel Regulation of Membrane Trafficking and Dominant-negative Effects by Misrouted Gonadotropin-releasing Hormone Receptor Mutants*

  2005cited by this paper
• In vitro coexpression and pharmacological rescue of mutant gonadotropin-releasing hormone receptors causing hypogonadotropic hypogonadism in humans expressing compound heterozygous alleles.

  2005cited by this paper
• Beyond the signal sequence: protein routing in health and disease.

  2005cited by this paper
• Heterodimerization with β2-Adrenergic Receptors Promotes Surface Expression and Functional Activity of α1D-Adrenergic Receptors

  2005cited by this paper
• RTP family members induce functional expression of mammalian odorant receptors.

  2004cited by this paper
• Human loss-of-function gonadotropin-releasing hormone receptor mutants retain wild-type receptors in the endoplasmic reticulum: molecular basis of the dominant-negative effect.

  2004cited by this paper
• The organization of engaged and quiescent translocons in the endoplasmic reticulum of mammalian cells

  2004cited by this paper
• Structure-Activity Relations of Successful Pharmacologic Chaperones for Rescue of Naturally Occurring and Manufactured Mutants of the Gonadotropin-Releasing Hormone Receptor

  2003cited by this paper
• Formation of stacked ER cisternae by low affinity protein interactions

  2003cited by this paper
• Dominant-negative action of disease-causing gonadotropin-releasing hormone receptor (GnRHR) mutants: a trait that potentially coevolved with decreased plasma membrane expression of GnRHR in humans.

  2003cited by this paper
• Molecular basis of hypogonadotropic hypogonadism: restoration of mutant (E(90)K) GnRH receptor function by a deletion at a distant site.

  2002cited by this paper
• Export from the Endoplasmic Reticulum Represents the Limiting Step in the Maturation and Cell Surface Expression of the Human δ Opioid Receptor*

  2000cited by this paper
• Pharmacological chaperones: a new twist on receptor folding.

  2000cited by this paper
• Multiple interactions of the Asp(2.61(98)) side chain of the gonadotropin-releasing hormone receptor contribute differentially to ligand interaction.

  2000cited by this paper
• Identification of Phe313 of the gonadotropin-releasing hormone (GnRH) receptor as a site critical for the binding of nonpeptide GnRH antagonists.

  2000cited by this paper
• MMFF VII. Characterization of MMFF94, MMFF94s, and other widely available force fields for conformational energies and for intermolecular‐interaction energies and geometries

  1999cited by this paper
• A Locus of the Gonadotropin-releasing Hormone Receptor That Differentiates Agonist and Antagonist Binding Sites (*)

  1995cited by this paper
• FLOG: A system to select ‘quasi-flexible’ ligands complementary to a receptor of known three-dimensional structure

  1994cited by this paper
• Distance Geometry and Molecular Conformation

  1988cited by this paper
• Use of lithium ion in measurement of stimulated pituitary inositol phospholipid turnover.

  1987cited by this paper
• Use of lithium ion in measurement of stimulated pituitary inositol phospholipid turnover.

  1987cited by this paper
• Numbers of receptor sites from Scatchard graphs: facts and fantasies.

  1982cited by this paper
• 0013-7227/02/$15.00/0 The Journal of Clinical Endocrinology & Metabolism 87(7):3255–3262 Printed in U.S.A. Copyright © 2002 by The Endocrine Society Rescue of Hypogonadotropic Hypogonadism-Causing and Manufactured GnRH Receptor Mutants by a Specific Prote

  year unknowncited by this paper

• Exploring the binding sites of VRT534 at Cx26 as a putative chemical chaperone for targeted treatment of hereditary hearing disorders

  2025cites this paper
• Mechanisms governing GPCR anterograde transport

  2025cites this paper
• Folding, misfolding, and regulation of intracellular traffic of G protein-coupled receptors involved in the hypothalamic-pituitary-gonadal axis.

  2025cites this paper
• Restoring function to inactivating G protein‐coupled receptor variants in the hypothalamic–pituitary–gonadal axis 1

  2024cites this paper
• Non-canonical signaling initiated by hormone-responsive G protein-coupled receptors from subcellular compartments.

  2024cites this paper
• Gonadotropin-Releasing Hormone Receptor (GnRHR) and Hypogonadotropic Hypogonadism

  2023cites this paper
• Targeting trafficking as a therapeutic avenue for misfolded GPCRs leading to endocrine diseases

  2022cites this paper
• Chronic estrus disrupts uterine gland development and homeostasis.

  2022cites this paper
• Misfolded G Protein-Coupled Receptors and Endocrine Disease. Molecular Mechanisms and Therapeutic Prospects

  2021cites this paper
• Intracellular Trafficking of G Protein-Coupled Receptors to the Cell Surface Plasma Membrane in Health and Disease

  2021cites this paper
• Protein homeostasis and regulation of intracellular trafficking of G protein-coupled receptors

  2020cites this paper
• Mutations in G Protein–Coupled Receptors: Mechanisms, Pathophysiology and Potential Therapeutic Approaches

  2020influential citation
• Modulation of proteostasis and protein trafficking: a therapeutic avenue for misfolded G protein-coupled receptors causing disease in humans.

  2019cites this paper
• Therapeutic strategies for diseases caused by loss-of-function mutations in G protein-coupled receptors.

  2019cites this paper
• Glu2.53(90) of the GnRH receptor is part of the conserved G protein-coupled receptor structure and does not form a salt-bridge with Lys3.32(121).

  2019cites this paper
• Glycosylation and dimerization of the human δ-opioid receptor polymorphic variants

  2018cites this paper
• Pharmacoperone drugs: targeting misfolded proteins causing lysosomal storage-, ion channels-, and G protein-coupled receptors-associated conformational disorders

  2018influential citation
• Chronic estrus disrupts uterine gland development and homeostasis

  2018cites this paper
• The role of the GLU2.53(90) residue in gonadotropin-releasing hormone receptor expression and function

  2017cites this paper
• Pharmacoperone rescue of vasopressin 2 receptor mutants reveals unexpected constitutive activity and coupling bias

  2017cites this paper
• Gonadotropin-Releasing Hormone (GnRH) Receptor Structure and GnRH Binding

  2017cites this paper
• The gonadotropin-releasing hormone system: Perspectives from reproduction to cancer (Review).

  2016cites this paper
• GnRH Action: GnRH Signaling

  2016cites this paper
• Pharmacoperones as a New Therapeutic Approach: In Vitro Identification and In vivo Validation of Bioactive Molecules.

  2016cites this paper
• Transitioning pharmacoperones to therapeutic use: in vivo proof-of-principle and design of high throughput screens.

  2014cites this paper
• Intracellular Trafficking of G Protein-Coupled Receptors to the Plasma Membrane in Health and Disease

  2014cites this paper
• A Phenotypic High Throughput Screening Assay for the Identification of Pharmacoperones for the Gonadotropin Releasing Hormone Receptor

  2014cites this paper
• Mutations in G protein-coupled receptors that impact receptor trafficking and reproductive function.

  2014influential citation
• Chaperoning G protein-coupled receptors: from cell biology to therapeutics.

  2014cites this paper
• TACR3 mutations disrupt NK3R function through distinct mechanisms in GnRH‐deficient patients

  2014cites this paper
• GPCR oligomerization and receptor trafficking.

  2013cites this paper
• Restoration of testis function in hypogonadotropic hypogonadal mice harboring a misfolded GnRHR mutant by pharmacoperone drug therapy

  2013cites this paper
• Regulatory processes governing the cell surface expression of LH and FSH receptors.

  2012cites this paper
• Behind the curtain: cellular mechanisms for allosteric modulation of calcium‐sensing receptors

  2012cites this paper
• Protein misfolding and neurodegeneration; new approaches to combat toxic misfolded proteins

  2012cites this paper
• Pharmacological chaperones correct misfolded GPCRs and rescue function: protein trafficking as a therapeutic target.

  2012cites this paper
• Rescue of misrouted GnRHR mutants reveals its constitutive activity.

  2012influential citation
• GPCR Signalling Complexes – Synthesis, Assembly, Trafficking and Specificity

  2012cites this paper
• Mice harboring Gnrhr E90K, a mutation that causes protein misfolding and hypogonadotropic hypogonadism in humans, exhibit testis size reduction and ovulation failure.

  2012cites this paper
• Discovery and validation of potential drug targets based on the phylogenetic evolution of GPCRs

  2012cites this paper
• Themed section: molecular pharmacology of GPCRs

  2012cites this paper
• Therapeutic Rescue of Misfolded Mutants: Validation of Primary High Throughput Screens for Identification of Pharmacoperone Drugs

  2011cites this paper
• The counter ion: expanding excipient functionality

  2011cites this paper
• Pharmacological chaperones for misfolded gonadotropin-releasing hormone receptors.

  2011influential citation
• Pharmacoperones: a new therapeutic approach for diseases caused by misfolded G protein-coupled receptors.

  2011cites this paper
• Biochemical mechanism of pathogenesis of human gonadotropin-releasing hormone receptor mutants Thr104Ile and Tyr108Cys associated with familial hypogonadotropic hypogonadism.

  2011influential citation
• Pharmacoperone Identification for Therapeutic Rescue of Misfolded Mutant Proteins

  2011cites this paper
• Salt Bridges Overlapping the Gonadotropin-Releasing Hormone Receptor Agonist Binding Site Reveal a Coincidence Detector for G Protein-Coupled Receptor Activation

  2011influential citation
• Exploring the structure, function & regulation of the human glucagon-like peptide-1 receptor

  2011cites this paper
• Salt bridge integrates GPCR activation with protein trafficking

  2010influential citation
• Non-syndromic congenital hypogonadotropic hypogonadism: clinical presentation and genotype-phenotype relationships.

  2010cites this paper
• GABA acts as a ligand chaperone in the early secretory pathway to promote cell surface expression of GABAA receptors.

  2010cites this paper
• Use of pharmacoperones to reveal GPCR structural changes associated with constitutive activation and trafficking.

  2010cites this paper
• Trafficking of G-protein-coupled receptors to the plasma membrane: insights for pharmacoperone drugs.

  2010cites this paper
• Calcium-sensing Receptor Biosynthesis Includes a Cotranslational Conformational Checkpoint and Endoplasmic Reticulum Retention*

  2010cites this paper
• Drug development and the cellular quality control system.

  2009cites this paper
• Trafficking and quality control of the gonadotropin releasing hormone receptor in health and disease.

  2009cites this paper